#NEWS: Our first-in-class SIRPα immuno-oncology program, initiated by OSE Immunotherapeutics, is moving to the next phase in clinical development. Based on the positive data from our first clinical studies and the switch to an improved antibody we aim to provide innovative immuno-oncology treatments to the benefit of more people. Learn more: https://bit.ly/4cHPzd8 #Cancer #ImmunoOncology #ResearchAndDevelopment
Congrats to BI and OSE teams on this exciting news! As a big believer in immune modulatory pathways validated by viral mimicry, I am very pleased to see this program moving forward. Best of luck with the next phase of this program!
Exciting news! Looking forward to the advancements in immuno-oncology with OSE Immunotherapeutics' SIRPα program moving to the next phase. Promising innovation for cancer treatment! #Cancer #ImmunoOncology #ResearchAndDevelopment
Great news Boehringer Ingelheim - all the best to make it accessible to everyone soon!
Boehringer Ingelheim best of luck for future Studies!
Excited to see our first-in-class SIRPα immuno-oncology program is one step closer to help patients in need!
Exciting news & times to come to make it accessible to everyone soon!
Great to see that our partnership with OSE Immunotherapeutics is harvesting successes! Nicolas Poirier Alexis PEYROLES Scott DeWire Oliver Kast Jonathon Sedgwick Ioannis Sapountzis hope to celebrate one day altogether if this therapy makes it to cancer patients!
Well done!
Awesome Boehringer Ingelheim
Senior Vice President and Global Head Discovery Research at AbbVie
1moPleased to see this MOA continuing to be tested by directly blocking the inhibitory receptor. All good luck with future studies.